|
Innovation Pathway Poses Risks to Device Innovation, Industry Says
The FDA should be cautious before entering into agreements via the Innovation Pathway that foster device development at research and academic centers, industry insiders urge.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives